Sabal Trust CO decreased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 16.0% during the first quarter, according to its most recent filing with the SEC. The firm owned 9,932 shares of the biopharmaceutical company’s stock after selling 1,895 shares during the period. Sabal Trust CO’s holdings in Bristol-Myers Squibb were worth $474,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the business. Capital Financial Planning LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth $28,000. Well Done LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth $30,000. Riverview Trust Co purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth $33,000. Trust Department MB Financial Bank N A purchased a new stake in Bristol-Myers Squibb in the 1st quarter worth $32,000. Finally, Portfolio Solutions LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth $37,000. Hedge funds and other institutional investors own 74.09% of the company’s stock.
A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Thursday, March 28th. BMO Capital Markets raised their price objective on Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 4th. Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective for the company. in a research report on Monday. Finally, Bank of America cut their price objective on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research report on Tuesday, February 19th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $56.88.
NYSE BMY traded up $0.31 during trading on Wednesday, hitting $47.74. The stock had a trading volume of 8,758,808 shares, compared to its average volume of 18,652,727. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.93 and a quick ratio of 1.79. The company has a market cap of $77.58 billion, a P/E ratio of 11.99, a PEG ratio of 2.19 and a beta of 0.77. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.01. The business had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The firm’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.94 earnings per share. As a group, equities research analysts expect that Bristol-Myers Squibb Co will post 4.18 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were bought at an average cost of $47.29 per share, with a total value of $236,450.00. Following the completion of the acquisition, the director now directly owns 27,000 shares in the company, valued at approximately $1,276,830. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Karen Murphy Santiago sold 3,065 shares of Bristol-Myers Squibb stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the transaction, the insider now directly owns 3,066 shares in the company, valued at $145,818.96. The disclosure for this sale can be found here. Company insiders own 0.12% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Sabal Trust CO Cuts Stake in Bristol-Myers Squibb Co (NYSE:BMY)” was first reported by Sundance Herald and is the sole property of of Sundance Herald. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://sundanceherald.com/2019/05/22/sabal-trust-co-has-474000-stake-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.